文献速递心脏核医学肿瘤 PET/CT

瑞加诺生心率反应迟钝可预测心血管风险并超越PET心肌血流定量

Blunted heart rate response to regadenoson predicts cardiovascular risk beyond quantitative positron emission tomography myocardial blood flow.
PubMed 文献 · J Nucl Cardiol · 2026-05-25

本研究回顾性分析4611例接受静息-负荷82Rb PET/CT患者,评估瑞加诺生负荷时心率反应迟钝(HRR<20%)对主要不良心血管事件(MACE)的预后价值。结果显示HRR迟钝者MACE发生率显著更高(16.2 vs 5.5事件/100患者年;校正HR 1.70,95%CI 1.50-1.94;P<.001),且独立于负荷心肌血流(sMBF)和心肌血流储备(MFR)。将HRR加入含临床特征和MBF的模型可改善预后判别与再分类(ΔAUC +0.017;NRI 0.12;均P<.001)。

要点

  • 瑞加诺生负荷HRR<20%与MACE风险独立相关(校正HR 1.70,95%CI 1.50-1.94)。
  • HRR迟钝的预后价值不受sMBF或MFR状态影响,且风险随HRR降低而递增。
  • HRR加入临床+MBF模型可小幅提升判别与再分类能力(ΔAUC +0.017;NRI 0.12)。

核心结论

  • 瑞加诺生负荷心率反应迟钝是独立于PET心肌血流参数的心血管风险预测因子,并提供增量预后价值。

研究设计与样本

  • 回顾性分析2016至2022年连续接受静息-负荷82Rb PET/CT检查的4611例患者(63±11岁;54%女性)。

主要发现

  • 27%(1263例)患者存在HRR迟钝,其异常sMBF(49% vs 27%)和异常MFR(66% vs 30%)患病率更高。
  • 中位随访3.3年(IQR 1.8-5.1),HRR迟钝者MACE发生率为16.2 vs 5.5事件/100患者年(校正HR 1.70,95%CI 1.50-1.94;P<.001)。
  • HRR与MACE风险呈非线性关联,风险随HRR降低而递增,且该关联不受sMBF或MFR状态影响。
  • 将HRR加入含关键临床特征和MBF的模型,判别能力与再分类均改善(ΔAUC +0.017;NRI 0.12;均P<.001)。

关键数值与推荐

  • 异常sMBF定义为<1.8 mL/min/g,异常MFR定义为<2.0。
  • HRR计算公式为(峰值心率-静息心率)/静息心率,HRR<20%定义为迟钝。
  • MACE定义为死亡、心肌梗死、卒中或心力衰竭住院。

临床怎么用

  • 在瑞加诺生负荷PET/CT报告中,除sMBF和MFR外,应关注心率反应,HRR<20%提示自主神经功能异常并提示更高心血管风险。
  • 对于sMBF和MFR正常的患者,若HRR迟钝,仍应视为心血管风险增高人群,考虑加强风险因素管理和随访。

局限性

  • 本研究为单中心回顾性设计,结果需前瞻性多中心验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the incremental prognostic value of a blunted heart rate response (HRR) to regadenoson beyond PET-derived myocardial flow parameters. BACKGROUND: A blunted HRR during pharmacologic stress with regadenoson, an adenosine A2A receptor agonist, may reflect autonomic dysfunction and heightened cardiovascular (CV) risk. Whether HRR provides prognostic information beyond stress myocardial blood flow (sMBF) and myocardial flow reserve (MFR) remains uncertain. METHODS: We retrospectively analyzed consecutive rest-stress 82Rb PET/CT studies performed between 2016 and 2022. Abnormal sMBF and MFR were defined as less than 1.8 mL/min/g and <2.0, respectively. HRR was calculated as (peak HR - rest HR)/rest HR and considered blunted if less than 20%. We compared differences in major adverse cardiovascular events (MACE: death, myocardial infarction, stroke, or heart failure hospitalization) between patients with blunted and normal HRR using multivariable Cox regression, stratified by sMBF and MFR. Nonlinear associations between HRR and MACE were evaluated using restricted cubic splines. Incremental prognostic value was assessed by changes in the area under the receiver-operating characteristic curve (AUC) and net reclassification index (NRI). RESULTS: Among 4611 patients (63 ± 11 years; 54% female), 1263 (27%) had blunted HRR. These patients had a higher prevalence of abnormal sMBF (49% vs 27%) and MFR (66% vs 30%). Over a median follow-up of 3.3 years (IQR 1.8-5.1), MACE rates were higher among patients with blunted HRR (16.2 vs 5.5 events/100 patient-years; adjusted HR 1.70 [95% CI: 1.50-1.94]; P < .001), irrespective of sMBF or MFR status. Risk increased progressively with lower HRR. Adding HRR to a model with key clinical characteristics and MBF improved prognostic discrimination and reclassification (ΔAUC +0.017; NRI 0.12; all P < .001). CONCLUSIONS: Blunted HRR to regadenoson is independently associated with higher CV risk and provides incremental prognostic value beyond PET myocardial flow.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Barreto J, Vashist A, Gallegos Kattan C, et al. Blunted heart rate response to regadenoson predicts cardiovascular risk beyond quantitative positron emission tomography myocardial blood flow. J Nucl Cardiol. 2026. PMID: 42190937. doi:10.1016/j.nuclcard.2026.102766

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。